Cancer Radiotherapie最新文献

{"title":"General technical considerations on reirradiation and focus on brain and head and neck tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique","authors":"Alexandre Escande,&nbsp;Yuedan Zhou,&nbsp;Myriam Ayadi,&nbsp;Jonathan Khalifa,&nbsp;Cyrus Chargari,&nbsp;Valentine Guimas,&nbsp;Marie-Pierre Sunyach,&nbsp;Delphine Antoni,&nbsp;Anne Laprie,&nbsp;Yoann Pointreau,&nbsp;Arnaud Beddok,&nbsp;Stéphane Supiot","doi":"10.1016/j.canrad.2026.104876","DOIUrl":"10.1016/j.canrad.2026.104876","url":null,"abstract":"<div><div>The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making relies on a delicate balance between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized data, there is an increasing number of data encouraging its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from supranational scientific societies, the following publication is based on the “Recommendations Commission” of the Société française de radiothérapie oncologique (the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on brain tumours and head and neck cancers.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104876"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential diagnosis of imaging alterations after stereotactic radiotherapy of brain metastases: A narrative review","authors":"Lara Caglayan,&nbsp;Mathias Sempels,&nbsp;Lieselotte Lauwens,&nbsp;Jean-François Daisne","doi":"10.1016/j.canrad.2026.104859","DOIUrl":"10.1016/j.canrad.2026.104859","url":null,"abstract":"<div><h3>Purpose</h3><div>Stereotactic radiotherapy is a key treatment for brain metastases, alongside surgery and systemic therapies. A substantial proportion of patients develop radiation necrosis after stereotactic radiotherapy. Differentiating radiation necrosis from tumour progression is critical, as they require distinct therapeutic strategies. While magnetic resonance imaging remains the mainstay of surveillance, its limitations emphasize the need for alternative, non-invasive diagnostic modalities. This narrative review aimed to summarize recent imaging techniques for distinguishing radiation necrosis from tumour progression after stereotactic radiotherapy for brain metastases.</div></div><div><h3>Materials and methods</h3><div>A systematic literature search was conducted in Embase and Medline (using the search engine PubMed) for studies published between January 2012 and February 2025. The terms “radiation necrosis,” “brain metastasis,” and “diagnosis” were combined. Eligible studies included adult patients with brain metastases treated with stereotactic radiation, with differentiation of radiation necrosis from tumour progression assessed by histopathology or imaging follow-up. Studies exclusively on primary brain tumours or without separate brain metastases analysis were excluded. Both prospective and retrospective designs were considered.</div></div><div><h3>Results</h3><div>Fourty studies met inclusion criteria: magnetic resonance imaging (<em>n</em> <!-->=<!--> <!-->21), nuclear medicine (<em>n</em> <!-->=<!--> <!-->13), and radiomics (<em>n</em> <!-->=<!--> <!-->6). Advanced magnetic resonance imaging (e.g., perfusion, intravoxel incoherent motion, treatment response assessment maps) and aminoacid positron-emission tomography showed the highest diagnostic accuracies. Radiomics, especially multiparametric approaches, improved performance but lacked external validation.</div></div><div><h3>Conclusion</h3><div>Combined advanced magnetic resonance imaging, aminoacid positron-emission tomography, and radiomics approaches offer the greatest potential. Prospective studies are needed.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104859"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern adjuvant radiotherapy for breast adenoid cystic carcinoma: Clinical outcomes across normofractionated and hypofractionated schedules","authors":"Sébastien Laroze,&nbsp;Youlia Kirova,&nbsp;Pierre Loap","doi":"10.1016/j.canrad.2026.104863","DOIUrl":"10.1016/j.canrad.2026.104863","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Breast adenoid cystic carcinoma is a rare triple-negative breast cancer subtype with a favourable prognosis. While hypofractionated and ultra-hypofractionated radiotherapy are increasingly used for breast cancer, no dedicated data exist for breast adenoid cystic carcinoma. This study reports contemporary oncological outcomes, radiotherapy parameters, and toxicity in a uniformly treated single-institution cohort.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Breast adenoid cystic carcinoma is a rare triple-negative breast cancer subtype with a favourable prognosis. While hypofractionated and ultra-hypofractionated radiotherapy are increasingly used for breast cancer, no dedicated data exist for breast adenoid cystic carcinoma. This study reports contemporary oncological outcomes, radiotherapy parameters, and toxicity in a uniformly treated single-institution cohort.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patients and methods&lt;/h3&gt;&lt;div&gt;We retrospectively reviewed files of all patients with non-metastatic breast adenoid cystic carcinoma treated with surgery and adjuvant radiation between 2006 and 2023. Clinical, pathological, treatment, and follow-up data were analysed. Survival was estimated using Kaplan-Meier methods.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;We retrospectively reviewed files of all patients with non-metastatic breast adenoid cystic carcinoma treated with surgery and adjuvant radiation between 2006 and 2023. Clinical, pathological, treatment, and follow-up data were analysed. Survival was estimated using Kaplan-Meier methods.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The data from 13 women (median age 69 years, range 47–79 years) were included; 92.3 % underwent breast-conserving surgery, and all were node-negative. Hypofractionation was used in 69.2 %, including three ultra-hypofractionated regimens (32.5 Gy delivered in five fractions). At a median follow-up of 60 months, there were no regional or distant recurrences and one local recurrence salvaged surgically. Five- and 10-year cancer-specific survival rates were 100 %, overall survival rates were 90.0 % and 67.5 %, respectively, and local recurrence-free survival rate was 90.0 % at both time points. Eight patients developed grade 1 acute radiodermatitis; no other acute or late toxicity events were observed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;The data from 13 women (median age 69 years, range 47–79 years) were included; 92.3 % underwent breast-conserving surgery, and all were node-negative. Hypofractionation was used in 69.2 %, including three ultra-hypofractionated regimens (32.5 Gy delivered in five fractions). At a median follow-up of 60 months, there were no regional or distant recurrences and one local recurrence salvaged surgically. Five- and 10-year cancer-specific survival rates were 100 %, overall survival rates were 90.0 % and 67.5 %, respectively, and local recurrence-free survival rate was 90.0 % at both time points. Eight patients developed grade 1 acute radiodermatitis; no other acute or late toxicity events were observed.&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclu","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104863"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial mesenchymal tumours with FET::CREB fusions: Two case reports and literature review","authors":"Quentin Josset,&nbsp;Josue Biaou,&nbsp;Loic Feuvret,&nbsp;Jihad Aslaoui,&nbsp;Delphine Caron","doi":"10.1016/j.canrad.2026.104860","DOIUrl":"10.1016/j.canrad.2026.104860","url":null,"abstract":"<div><div>Intracranial mesenchymal tumours with in-frame gene fusions of the FET family of RNA-binding proteins to the cyclic AMP response element-binding protein family of transcription factors are exceptionally rare primary central nervous system neoplasms, with morphological similarities to angiomatoid fibrous histiocytoma. Despite their recent inclusion in the 2021 World Health Organisation classification of tumours of the central nervous system, only a limited number of cases have been reported. We describe two cases of intracranial mesenchymal tumours harbouring fusion of the Ewing sarcoma breakpoint region 1 gene with the activating transcription factor 1 gene, both arising from the falx cerebri. Clinical, radiological, pathological, molecular, and therapeutic findings are detailed. A literature review was performed to contextualize our observations. Case 1 involved a 32-year-old man with a parafalcine lesion initially mimicking meningioma, treated with subtotal resection followed by adjuvant radiotherapy. Case 2 concerned a 69-year-old woman with a similar lesion, managed with gross total resection and radiotherapy. Histopathology in both cases revealed epithelioid morphology within myxoid or fibrous stroma, with desmin, epithelial membrane antigen, and CD99 positivity. Molecular analyses confirmed fusion of the Ewing sarcoma breakpoint region 1 gene with the activating transcription factor 1 gene. After 38 and 30 months of follow-up, respectively, both patients remained recurrence-free. These cases reinforce the recognition of intracranial mesenchymal tumours with gene fusions of the FET family of RNA-binding proteins to the cyclic AMP response element-binding protein family of transcription factors as a distinct entity. Accurate diagnosis requires combined histopathological and molecular evaluation. While gross total resection remains the preferred approach, adjuvant radiotherapy may improve disease control. Larger multicentre studies are needed to refine prognostic factors and therapeutic recommendations.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104860"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer: A population-based study”, Cheptea C, Kirova Y, Fourquet A, Loap P. Cancer Radiother 2026;30:104828","authors":"Zeina Ayoub,&nbsp;Tarek Al Bitar,&nbsp;Toufic Eid","doi":"10.1016/j.canrad.2026.104862","DOIUrl":"10.1016/j.canrad.2026.104862","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104862"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatially fractionated radiotherapy as an alternative to brachytherapy for cervical cancer with unfavourable dosimetry: An in-silico study","authors":"Ankita Gupta,&nbsp;Tejaswi S. Kanala,&nbsp;Prakash Shinde,&nbsp;Kishore Joshi,&nbsp;Jaahid Mulani,&nbsp;Kunal Prajapati,&nbsp;Jeevanshu Jain,&nbsp;Prachi Mittal,&nbsp;Supriya Chopra","doi":"10.1016/j.canrad.2026.104878","DOIUrl":"10.1016/j.canrad.2026.104878","url":null,"abstract":"<div><h3>Purpose</h3><div>Brachytherapy is a critical component of cervical cancer treatment, but unfavourable anatomy or poor tumour response to external beam radiotherapy can make brachytherapy technically difficult or suboptimal, resulting in inadequate target coverage or unacceptable organ-at-risk doses. This study evaluated the dosimetric feasibility of spatially fractionated radiotherapy as an alternative boost option when brachytherapy cannot be optimally delivered.</div></div><div><h3>Materials and methods</h3><div>An in-silico study was performed using volumetric-modulated arc therapy-based spatially fractionated radiotherapy on imaging data from ten patients who received brachytherapy between 2018 and 2021. These patients had suboptimal brachytherapy dosimetry due to unfavourable anatomy and/or large residual disease, or required advanced intracavitary–interstitial techniques. Before brachytherapy, magnetic resonance imaging was used to delineate the high-risk clinical target volume, and organs-at-risk were contoured on contrast-enhanced computed tomography. Two spatially fractionated radiotherapy plans were developed: (i) using straight virtual “rods” and (ii) using bending “rods”. These virtual rods represented intentionally placed high-dose regions to recreate the heterogenous dose distribution characteristic of brachytherapy. Spatially fractionated radiotherapy plans were compared with clinically delivered brachytherapy plans.</div></div><div><h3>Results</h3><div>Both spatially fractionated radiotherapy approaches achieved high-risk clinical target D90 matching or exceeding brachytherapy across all patients. In cases with large residual tumours or unfavourable anatomy (<em>n</em> <!-->=<!--> <!-->7), spatially fractionated radiotherapy produced higher target coverage than brachytherapy. In patients with favourable intracavitary–interstitial brachytherapy dosimetry (<em>n</em> <!-->=<!--> <!-->3), spatially fractionated radiotherapy achieved comparable target doses. Bladder and rectum doses exceeded recommended constraints in seven of ten brachytherapy plans, whereas all spatially fractionated radiotherapy plans maintained organ-at-risk doses within recommended hard constraints.</div></div><div><h3>Conclusion</h3><div>Spatially fractionated radiotherapy may offer a feasible alternative boost strategy for patients in whom brachytherapy is technically limited or yields suboptimal dosimetry. While not intended to replace brachytherapy, it may help bridge treatment gaps in challenging clinical scenarios.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104878"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of cervical cancer with lymph nodes involvement in a large tertiary centre: Results from the preimmunotherapy era","authors":"Grégoire Laurent Delanghe,&nbsp;Alexandre Escande,&nbsp;Séverine Risbourg,&nbsp;Diane Sayadi,&nbsp;Alexandra Noeuvéglise,&nbsp;Aïcha Ben Miled,&nbsp;Camille Pasquesoone,&nbsp;Hortense Chevalier,&nbsp;Carlos Martinez-Gomez,&nbsp;Lucie Bresson,&nbsp;Anne-Sophie Navarro,&nbsp;Romain Cayez,&nbsp;Marie-Cécile Le Deley,&nbsp;Fabrice Narducci,&nbsp;Éric F. Lartigau,&nbsp;Abel Cordoba","doi":"10.1016/j.canrad.2026.104875","DOIUrl":"10.1016/j.canrad.2026.104875","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to assess the specific outcomes of patients locally advanced node-positive cervical cancer according to the International Federation of Gynaecology and Obstetrics receiving concurrent chemoradiotherapy and image-guided adaptive brachytherapy before adjuvant immunotherapy.</div></div><div><h3>Patients and methods</h3><div>A cohort of 388 women with non-metastatic advanced cervical cancer and lymph node involvement treated at a single tertiary centre (2016–2021) was analysed. All patients underwent chemoradiotherapy followed by brachytherapy. Disease-free survival and overall survival were compared between patients with only pelvic node involvement (<em>n</em> <!-->=<!--> <!-->175) and those with at least para-aortic node involvement (<em>n</em> <!-->=<!--> <!-->213), as well as across node staging methods. Notably, some patients also had bladder or rectal involvement.</div></div><div><h3>Results</h3><div>With a median follow-up of 54.8 months, 152 progressions or recurrences were reported, including metastatic event in 99 cases (65.1 % of first events). Additionally, 22 deaths occurred without previous progression/relapse. This resulted in a 5-year disease-free survival rate of 50.8 % (95 % confidence interval [CI]: 45.2–56.2 %) for the entire cohort, significantly differing between the pelvic (58.5 %; 95 % CI: 50.1–65.9 %) and para-aortic (44.2 %; 95 % CI: 36.7–51.4 %) groups (<em>p</em> <!-->=<!--> <!-->0.007). The 5-year overall survival rate was 61.0 % (95 % CI: 55.7–65.8 %) in the entire cohort and was poorer in patients with para-aortic involvement (52.5 %; 95 % CI: 45.1–59.3 %; <em>p</em> <!-->=<!--> <!-->0.002). A larger high-risk clinical target volume at least 43.5<!--> <!-->cm³ (<em>p</em> <!-->=<!--> <!-->0.0001), para-aortic node involvement (<em>p</em> <!-->=<!--> <!-->0.01), and a total treatment duration of more than 55 days (<em>p</em> <!-->=<!--> <!-->0.01) were associated with a higher recurrence risk.</div></div><div><h3>Conclusion</h3><div>Chemoradiotherapy followed by brachytherapy is effective and feasible for patients with node-positive cervical cancer. However, two-thirds of progressions or recurrences involved a distant event, suggesting the need to evaluate incremental systemic treatment strategies.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104875"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “Radiotherapy and brachytherapy in the management of adult soft tissue sarcomas” [Cancer Radiother. 30 (2026) 104805]","authors":"Benoît Allignet,&nbsp;Carmen Llacer,&nbsp;Anne Ducassou,&nbsp;Pauline Gillon,&nbsp;Luc Ollivier,&nbsp;Marie-Pierre Sunyach,&nbsp;Augustin Mervoyer,&nbsp;Laurence Moureau-Zabotto,&nbsp;Marie-Claude Biston,&nbsp;Juliette Thariat,&nbsp;Cécile Le Péchoux","doi":"10.1016/j.canrad.2026.104874","DOIUrl":"10.1016/j.canrad.2026.104874","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104874"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Comments on ‘Contemporary survival outcomes of patients with isolated nodal recurrences of breast cancer”’, Ayoub Z, Al Bitar T, Eid T. Cancer Radiother 2026;30:104861","authors":"Cezara Cheptea,&nbsp;Youlia Kirova,&nbsp;Alain Fourquet,&nbsp;Pierre Loap","doi":"10.1016/j.canrad.2026.104861","DOIUrl":"10.1016/j.canrad.2026.104861","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104861"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival outcomes of trimodal treatment for stage IVB endometrial cancer: A retrospective single-centre cohort study","authors":"Alexandra Noeuveglise,&nbsp;Kanta Ka,&nbsp;Alexandre Escande,&nbsp;Elena Cerezo,&nbsp;Audrey Parent,&nbsp;Cécile Le Deley,&nbsp;Cyril Abdedaim,&nbsp;Antonin Broyelle,&nbsp;Fabrice Narducci,&nbsp;Carlos Martinez,&nbsp;Anne-Sophie Navarro,&nbsp;Lucie Bresson,&nbsp;Éric Lartigau,&nbsp;Abel Cordoba","doi":"10.1016/j.canrad.2026.104877","DOIUrl":"10.1016/j.canrad.2026.104877","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study was to evaluate survival outcomes of multimodal treatment, including chemotherapy, surgery, and radiotherapy, of patients with stage IVB endometrial carcinoma treated at a single institution.</div></div><div><h3>Materials and methods</h3><div>We retrospectively identified 56 patients with stage IVB according to the International Federation of Gynaecology and Obstetrics endometrial carcinoma treated between 2004 and 2017. All patients received chemotherapy. Survival outcomes were analysed in the overall cohort and according to treatment strategies.</div></div><div><h3>Results</h3><div>With a median follow-up of 7.5 years, overall survival rates at 2, 3, and 5 years were 57.1 %, 46.4 %, and 32.1 %, respectively. Progression-free survival rates at 2, 3, and 5 years were 35.7 %, 28.6 %, and 23.2 %, respectively. Patients with a single metastatic site had significantly better outcomes compared with those with multiple metastatic sites. Among patients undergoing trimodal therapy, survival outcomes were more favourable, particularly in those with limited metastatic burden.</div></div><div><h3>Conclusion</h3><div>Multimodal treatment including surgery and radiotherapy was associated with improved survival outcomes in selected patients with stage IVB endometrial cancer. These findings support a personalized treatment strategy based on metastatic burden and response to systemic therapy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"30 4","pages":"Article 104877"},"PeriodicalIF":1.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149032213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}